US approvals of high-risk medical devices are way down.
Shareholders are rewarding the kinds of companies they punished a year ago.
Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
The FDA is loosening its rules on the authorisation of diagnostic tests for the new coronavirus, but it is still some way behind Europe.
The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.
Toothy grins all round at Align, but it is unclear how much longer it can keep up its scorching rate of sales growth.